ATAI Life Sciences N.V’s filing revealed that its Officer SAHIL KIRPEKAR acquired Company’s shares for reported $0.23 million on Jul 02 ’25. In the deal valued at $2.81 per share,83,332 shares were bought.
Then, SAHIL KIRPEKAR bought 106,093 shares, generating $294,381 in total proceeds.
Before that, SAHIL KIRPEKAR bought 80,000 shares. ATAI Life Sciences N.V shares valued at $198,408 were divested by the Officer at a price of $2.48 per share.
Oppenheimer initiated its ATAI Life Sciences N.V [ATAI] rating to an Outperform in a research note published on July 29, 2025; the price target was $14. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid November has reiterated a ‘”a Buy”‘ rating for it. Maxim Group also remained covering ATAI and has increased its forecast on April 03, 2024 with a “Buy” recommendation from previously “Hold” rating. Loop Capital started covering the stock on November 01, 2022. It rated ATAI as “a Buy”.
Price Performance Review of ATAI
On Friday, ATAI Life Sciences N.V [NASDAQ:ATAI] saw its stock fall -0.48% to $4.13. Over the last five days, the stock has lost -0.96%. ATAI Life Sciences N.V shares have risen nearly 201.46% since the year began. Nevertheless, the stocks have risen 210.53% over the past one year.
How much short interest is there in ATAI Life Sciences N.V?
A steep rise in short interest was recorded in ATAI Life Sciences N.V stocks on 2025-07-15, growing by 5.21 million shares to a total of 16.18 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 10.96 million shares. There was a rise of 32.22%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 30, 2021 when Maxim Group began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
